

# **Solid Tumor Therapeutics Market Size, Trends, Analysis, and Outlook By Cancer (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others), By Drug (Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Doxorubicin, Bevacizumab, Erlotinib, Sunitinib, Everolimusa, Others), by Country, Segment, and Companies, 2024-2032**

<https://marketpublishers.com/r/S50F1DE63452EN.html>

Date: April 2024

Pages: 205

Price: US\$ 3,980.00 (Single User License)

ID: S50F1DE63452EN

## **Abstracts**

The global Solid Tumor Therapeutics market size is poised to register 11.2% growth from 2024 to 2032, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Solid Tumor Therapeutics market across By Cancer (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others), By Drug (Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Doxorubicin, Bevacizumab, Erlotinib, Sunitinib, Everolimusa, Others)

The solid tumor therapeutics market is influenced by advances in cancer biology, molecular profiling, and targeted therapies offering personalized treatment options for patients with solid tumors such as lung cancer, breast cancer, and colorectal cancer. With a growing emphasis on precision medicine and combination therapies, there's a demand for innovative therapeutics targeting tumor-specific mutations, signaling pathways, and immune checkpoints to improve treatment efficacy and patient outcomes. By 2030, the market is poised to witness expanded indications, biomarker-driven treatment algorithms, and adoption of immunotherapies, antibody-drug conjugates, and small molecule inhibitors, enabling tailored treatment strategies and improved survival rates for individuals with solid tumors across different cancer types

and stages.

## Solid Tumor Therapeutics Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Solid Tumor Therapeutics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Solid Tumor Therapeutics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Solid Tumor Therapeutics industry.

## Key market trends defining the global Solid Tumor Therapeutics demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

## Solid Tumor Therapeutics Market Segmentation- Industry Share, Market Size, and Outlook to 2032

The Solid Tumor Therapeutics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Solid Tumor Therapeutics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

## Key strategies adopted by companies within the Solid Tumor Therapeutics industry

Leading Solid Tumor Therapeutics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Solid Tumor Therapeutics companies.

## Solid Tumor Therapeutics Market Study- Strategic Analysis Review

The Solid Tumor Therapeutics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

**Industry Dynamics:** Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

**Strategic Insights:** Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

**Internal Strengths and Weaknesses:** Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

**Future Possibilities:** Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

## Solid Tumor Therapeutics Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Solid Tumor Therapeutics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.

## Solid Tumor Therapeutics Country Analysis and Revenue Outlook to 2032

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2032.

**North America Solid Tumor Therapeutics Market Size Outlook-** Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to \$4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various Solid Tumor Therapeutics market segments. Similarly, Strong market demand is encouraging Canadian Solid Tumor Therapeutics companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico Solid Tumor Therapeutics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Solid Tumor Therapeutics Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Solid Tumor Therapeutics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European Solid Tumor Therapeutics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Solid Tumor Therapeutics Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Solid Tumor Therapeutics in Asia Pacific. In particular, China, India, and South East Asian Solid Tumor Therapeutics markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.

## Latin America Solid Tumor Therapeutics Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

## Middle East and Africa Solid Tumor Therapeutics Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Solid Tumor Therapeutics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Solid Tumor Therapeutics.

## Solid Tumor Therapeutics Market Company Profiles

The global Solid Tumor Therapeutics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Abbott Laboratories Inc, Amgen Inc, AstraZeneca PLC, Baxter International Inc, Biogen Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC.

## Recent Solid Tumor Therapeutics Market Developments

The global Solid Tumor Therapeutics market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

## Solid Tumor Therapeutics Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

## Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

## Market Segmentation:

By Cancer

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Cervical Cancer

Others

By Drug

Carboplatin

Cisplatin

Gemcitabine

Paclitaxel

Doxorubicin

Bevacizumab

Erlotinib

Sunitinib

Everolimusa

Others

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

Abbott Laboratories Inc

Amgen Inc

AstraZeneca PLC

Baxter International Inc

Biogen Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche AG

GlaxoSmithKline PLC

Formats Available: Excel, PDF, and PPT



## Contents

### 1. EXECUTIVE SUMMARY

- 1.1 Solid Tumor Therapeutics Market Overview and Key Findings, 2024
- 1.2 Solid Tumor Therapeutics Market Size and Growth Outlook, 2021- 2030
- 1.3 Solid Tumor Therapeutics Market Growth Opportunities to 2030
- 1.4 Key Solid Tumor Therapeutics Market Trends and Challenges
  - 1.4.1 Solid Tumor Therapeutics Market Drivers and Trends
  - 1.4.2 Solid Tumor Therapeutics Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Solid Tumor Therapeutics Companies

### 2. SOLID TUMOR THERAPEUTICS MARKET SIZE OUTLOOK TO 2030

- 2.1 Solid Tumor Therapeutics Market Size Outlook, USD Million, 2021- 2030
- 2.2 Solid Tumor Therapeutics Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

### 3. SOLID TUMOR THERAPEUTICS MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
  - \* Threat of New Entrants
  - \* Threat of Substitutes
  - \* Intensity of Competitive Rivalry
  - \* Bargaining Power of Buyers
  - \* Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

### 4. SOLID TUMOR THERAPEUTICS MARKET SEGMENTATION ANALYSIS AND OUTLOOK

- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
  - By Cancer
    - Breast Cancer
    - Lung Cancer

Colorectal Cancer

Prostate Cancer

Cervical Cancer

Others

By Drug

Carboplatin

Cisplatin

Gemcitabine

Paclitaxel

Doxorubicin

Bevacizumab

Erlotinib

Sunitinib

Everolimusa

Others

4.3 Growth Prospects and Niche Opportunities, 2023- 2030

4.4 Regional comparison of Market Growth, CAGR, 2023-2030

## **5. REGION-WISE MARKET OUTLOOK TO 2030**

5.1 Key Findings for Asia Pacific Solid Tumor Therapeutics Market, 2025

5.2 Asia Pacific Solid Tumor Therapeutics Market Size Outlook by Type, 2021- 2030

5.3 Asia Pacific Solid Tumor Therapeutics Market Size Outlook by Application, 2021- 2030

5.4 Key Findings for Europe Solid Tumor Therapeutics Market, 2025

5.5 Europe Solid Tumor Therapeutics Market Size Outlook by Type, 2021- 2030

5.6 Europe Solid Tumor Therapeutics Market Size Outlook by Application, 2021- 2030

5.7 Key Findings for North America Solid Tumor Therapeutics Market, 2025

5.8 North America Solid Tumor Therapeutics Market Size Outlook by Type, 2021- 2030

5.9 North America Solid Tumor Therapeutics Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Solid Tumor Therapeutics Market, 2025

5.11 South America Pacific Solid Tumor Therapeutics Market Size Outlook by Type, 2021- 2030

5.12 South America Solid Tumor Therapeutics Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Solid Tumor Therapeutics Market, 2025

5.14 Middle East Africa Solid Tumor Therapeutics Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Solid Tumor Therapeutics Market Size Outlook by Application, 2021- 2030

## **6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030**

6.1 US Solid Tumor Therapeutics Market Size Outlook and Revenue Growth Forecasts

6.2 US Solid Tumor Therapeutics Industry Drivers and Opportunities

6.3 Canada Market Size Outlook and Revenue Growth Forecasts

6.4 Canada Solid Tumor Therapeutics Industry Drivers and Opportunities

6.6 Mexico Market Size Outlook and Revenue Growth Forecasts

6.6 Mexico Solid Tumor Therapeutics Industry Drivers and Opportunities

6.7 Germany Market Size Outlook and Revenue Growth Forecasts

6.8 Germany Solid Tumor Therapeutics Industry Drivers and Opportunities

6.9 France Market Size Outlook and Revenue Growth Forecasts

6.10 France Solid Tumor Therapeutics Industry Drivers and Opportunities

6.11 UK Market Size Outlook and Revenue Growth Forecasts

6.12 UK Solid Tumor Therapeutics Industry Drivers and Opportunities

6.13 Spain Market Size Outlook and Revenue Growth Forecasts

6.14 Spain Solid Tumor Therapeutics Industry Drivers and Opportunities

6.16 Italy Market Size Outlook and Revenue Growth Forecasts

6.16 Italy Solid Tumor Therapeutics Industry Drivers and Opportunities

6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts

6.18 Rest of Europe Solid Tumor Therapeutics Industry Drivers and Opportunities

6.19 China Market Size Outlook and Revenue Growth Forecasts

6.20 China Solid Tumor Therapeutics Industry Drivers and Opportunities

6.21 India Market Size Outlook and Revenue Growth Forecasts

6.22 India Solid Tumor Therapeutics Industry Drivers and Opportunities

6.23 Japan Market Size Outlook and Revenue Growth Forecasts

6.24 Japan Solid Tumor Therapeutics Industry Drivers and Opportunities

6.26 South Korea Market Size Outlook and Revenue Growth Forecasts

6.26 South Korea Solid Tumor Therapeutics Industry Drivers and Opportunities

6.27 Australia Market Size Outlook and Revenue Growth Forecasts

6.28 Australia Solid Tumor Therapeutics Industry Drivers and Opportunities

6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts

6.30 South East Asia Solid Tumor Therapeutics Industry Drivers and Opportunities

6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts

6.32 Rest of Asia Pacific Solid Tumor Therapeutics Industry Drivers and Opportunities

6.33 Brazil Market Size Outlook and Revenue Growth Forecasts

6.34 Brazil Solid Tumor Therapeutics Industry Drivers and Opportunities

- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Solid Tumor Therapeutics Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Solid Tumor Therapeutics Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Solid Tumor Therapeutics Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Solid Tumor Therapeutics Industry Drivers and Opportunities

## **7. SOLID TUMOR THERAPEUTICS MARKET OUTLOOK ACROSS SCENARIOS**

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

## **8. SOLID TUMOR THERAPEUTICS COMPANY PROFILES**

- 8.1 Profiles of Leading Solid Tumor Therapeutics Companies in the Market
- 8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
- 8.3 Financial Performance and Key Metrics
- Abbott Laboratories Inc
- Amgen Inc
- AstraZeneca PLC
- Baxter International Inc
- Biogen Inc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC.

## **9. APPENDIX**

- 9.1 Scope of the Report
- 9.2 Research Methodology and Data Sources
- 9.3 Glossary of Terms
- 9.4 Market Definitions
- 9.5 Contact Information

## I would like to order

Product name: Solid Tumor Therapeutics Market Size, Trends, Analysis, and Outlook By Cancer (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others), By Drug (Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Doxorubicin, Bevacizumab, Erlotinib, Sunitinib, Everolimus, Others), by Country, Segment, and Companies, 2024-2032

Product link: <https://marketpublishers.com/r/S50F1DE63452EN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S50F1DE63452EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970